Valneva Shares Plunge Despite Pfizer's Steady Commitment

Valneva shares crashed nearly 40% as a statistical nuance in Phase 3 data spooked investors, despite Pfizer's continued support for regulatory filings and a potential $143M milestone.

A vaccine candidate demonstrating over 70% efficacy would typically trigger a rally on the stock market. For Valneva, however, Monday presented a starkly different scenario. The release of Phase 3 trial data for its Lyme disease vaccine, developed in partnership with Pfizer, instead sparked a severe sell-off that at one point erased nearly 40% of the company's market value. This dramatic investor retreat stands in sharp contrast to Pfizer's unwavering stance, as the pharmaceutical giant continues to back their joint regulatory submission plans.

Investor Panic Over a Statistical Nuance

The collaborative vaccine candidate, PF-07307405, successfully prevented Lyme disease infections in the pivotal VALOR study, with no significant safety concerns identified. The catalyst for the market's negative reaction was buried deeper within the data. An unexpectedly low number of infection cases during the trial period caused the lower bound of the confidence interval in the first pre-specified analysis to fall just short of the required threshold, registering at 15.8% versus the 20% target.

The market's immediate punishment for this perceived lack of statistical robustness was severe, driving Valneva's share price down as much as 38% during the session. The stock ultimately closed at €2.83. This reaction underscores that investors are placing greater weight on the precise statistical significance of the primary endpoint than on the headline efficacy figure alone.

Pfizer Sees a Different Picture and Lucrative Incentives Remain

Pfizer's interpretation of the clinical results diverges completely from the market's knee-jerk response. The company highlights that a second, pre-defined analysis successfully cleared the statistical hurdle with a lower confidence interval bound of 21.7%. Consequently, Pfizer views the overall data package as sufficient to proceed.

Regulatory applications with both the U.S. FDA and the European Medicines Agency are still slated for submission later this year. The outcome is critically important for Valneva's financial future. A successful approval would trigger initial milestone payments totaling $143 million, supplemented by future sales-dependent royalty streams.

The vaccine project may also benefit from current U.S. health policy priorities, where the need for improved Lyme disease treatments has been explicitly emphasized by Health Secretary Robert F. Kennedy Jr. Regardless of the regulatory journey for the Lyme candidate, Valneva is concurrently advancing its second key pipeline asset. Initial data from two Phase 2 studies for its Shigella vaccine candidate are expected by mid-2026.

For now, the company's immediate focus remains fixed on the health authorities' review of the Lyme disease application. The planned market launch for the vaccine continues to target the second half of 2027.